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As our understanding of the biology of ductal carci-
noma in situ (DCIS) has increased, the management
approach to the axilla has evolved. DCIS, by deﬁni-
tion, cannot metastasize, and it has been known for
many years that nodal metastases, presumed to be
due to unrecognized invasion, are extremely uncom-
mon. In a National Cancer Database review of
10,946 patients with DCIS undergoing axillary dis-
section between 1985 and 1991, only 3.6% were
found to have axillary metastases,1 and this number is
even lower when only cases of screen-detected DCIS
are considered. The major impetus for nodal staging
in DCIS today is the recognized sampling error that
occurs when needle biopsy techniques are used for
diagnosis. In 1998, a joint committee of the American
College of Surgeons, American College of Radiolo-
gists, and College of American Pathologists devel-
oped a standard for the diagnosis and management of
DCIS which concluded that axillary dissection was
unnecessary for the majority of patients with DCIS.
Consideration of a level I dissection to avoid a second
surgical procedure for patients undergoing mastec-
tomy for extensive or high-grade DCIS was recom-
mended.2 When these guidelines were updated in
1992,3 they reﬂected both the emergence of sentinel
node biopsy as an axillary staging technique and the
low likelihood of identifying invasive carcinoma with
nodal disease in localized DCIS by recommending
that axillary staging in patients treated with breast-
conserving approaches be reserved for those found to
have invasion on ﬁnal pathologic evaluation. In
patients undergoing mastectomy, sentinel node
biopsy for axillary staging was recommended for
surgeons experienced in the technique; for those who
were not, a level I axillary dissection was suggested.
In this issue of the Annals of Surgical Oncology,
Porembka et al.4 use Surveillance, Epidemiology, and
End Results (SEER) data from 1988 through 2002 to
analyze axillary management in patients with DCIS.
Based on their analysis of 23,502 patients, they con-
clude that there is persistent and excessive utilization of
axillary nodal assessment, particularly axillary dissec-
tion, in patients with DCIS. The data as presented is
alarming, with 21% of those having surgery between
1998 and 2002 undergoing lymph node assessment. In
the group that had breast-conserving surgery (BCS),
67% of the nodal procedures were axillary dissections;
in the mastectomy group, 87% had axillary dissection.
There are several important caveats to these observa-
tions. First, the SEER database, while an excellent
source of high-quality, population-based cancer data,
may not be an ideal source for analyzing the nuances of
axillary surgery. SEER coding rules state that, if
axillary nodes are present in a mastectomy specimen,
the procedure should be coded as a modiﬁed radical
mastectomy rather than a simple mastectomy. The
removal of a few level 1 axillary nodes in order to
ensure removal of the axillary tail of the breast is not
uncommon, and certainly does not constitute a thera-
peutic axillary dissection, although it would be coded
as such by SEER rules. Thus, the most accurate
assessment of the use of axillary dissection is obtained
from the subset of women undergoing BCS. Based on
the authors’ statement that 70% of the 10,637 women
treated in the 1998–2002 timeperiod hadBCS, and that
589 had axillary staging, this results in about 395
axillary dissections, or 5% of the total group.
The second major issue regarding this work is that
the time period under study was the same time period
in which the sentinel node biopsy technique was being
validated, reﬁned, and disseminated. Two major
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clinical trials of sentinel node biopsy began patient
accrual in the USA in 1999, and sentinel node biopsy-
speciﬁc procedure codes only became available in
1999. Since that time, the body of evidence support-
ing the use of sentinel node biopsy as a safe and
eﬀective technique for axillary staging has expanded
exponentially, and rates of sentinel node biopsy use in
2002 have limited relevance to practice patterns in
2008. Chen et al.5 used data from 490,899 patients
with stage I and T2N0 stage 2 invasive carcinoma in
the National Cancer Database to examine trends in
the use of sentinel node biopsy and found that
patients diagnosed in 2005 had an odds ratio of 5.26
[95% conﬁdence interval (CI) 5.13–5.40] for sentinel
node biopsy compared with those diagnosed in 1998.
In this study, 65.5% of axillary staging in 2005 was
performed by sentinel node biopsy.
However, in spite of the increased use of sentinel
node biopsy today compared with in 2002, the over-
arching question that Porembka et al. bring to our
attention, the question of the appropriateness of any
axillary staging in the patientwithDCIS, is oneworthy
of serious consideration. There is clearly no indication
for axillary dissection as a staging procedure in the
patient with DCIS. Ample opportunities exist for
practising surgeons to learn the sentinel node biopsy
technique, and it is a routine part of residency training;
not knowinghow toperform theprocedure is no longer
a relevant excuse. It is equally apparent that routine
sentinel node biopsy in all patients with DCIS is also
not indicated. Data from the National Surgical Adju-
vant Breast and Bowel Project (NSABP) B17 and B24
trials document that the risk of axillary recurrence in
patients treated with breast-conserving surgery, with
or without radiation therapy and with or without
tamoxifen, is extremely low. In the NSABP B17 trial
the axillary recurrence rate was 0.83 per 1000 patient
years, and in NSABP B24 the rate was 0.36 per 1000
patient years.6 These low rates of axillary recurrence
make it impossible to justify the routine use of a pro-
cedure that is associated with a 7% incidence of
lymphedema and a 9% incidence of paresthesia 6
months postoperatively, as demonstrated in the
American College of Surgeons Z10 trial.7 A similar
incidence of arm sequelae at 1-year follow-up has been
reported in the Axillary Lymphatic Mapping against
Nodal Axillary Clearance (ALMANAC) trial.8 It is
well recognized that the likelihood of identifying
invasive carcinoma is higher in DCIS which is associ-
ated with a clinical or mammographic mass, in high-
grade lesions, and in lesions of larger size; however, the
majority of patients with DCIS with these features do
not have coexisting invasive carcinoma. At present, a
validated model to identify subsets of patients at truly
high risk for invasive cancer does not exist. In light of
this, in patients treatedwith breast-conserving surgery,
limiting sentinel node biopsy to those who have inva-
sive carcinoma in the lumpectomy specimen is cost
effective and minimizes unnecessary morbidity. The
situation in patients undergoing mastectomy is some-
what different. The risk of sampling error is highest in
patients with large areas of DCIS, and the opportunity
for sentinel node biopsy is lost once mastectomy is
performed, changing the risk–benefit ratio to favor
sentinel node biopsy, as suggested in current guide-
lines.9
The initial enthusiasm for the use of sentinel node
biopsy in the patient with DCIS anytime there is an
axilla in the vicinity should now be tempered by the
availability of high-quality empiric data from clinical
trials documenting both excellent outcomes in patients
with DCIS who do not undergo axillary staging, and
the small but real incidence of long-term sequelae in
patients who undergo the procedure.When tempted to
use sentinel node biopsy in a majority of patients with
DCIS ‘‘just to be safe,’’ it is worth remembering that a
fool with a tool is still a fool.
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